147 related articles for article (PubMed ID: 17532621)
21. [Expression of P53, P63, and C-erbB-2 in endometrioid adenocarcinoma and their clinicopathological significance].
Hu WF; Liu MQ; Zhao Q
Ai Zheng; 2004 Sep; 23(9):1021-5. PubMed ID: 15363194
[TBL] [Abstract][Full Text] [Related]
22. Expression of protease activated receptor-2 related to angiogenesis in tumor advancement of uterine endometrial cancers.
Jahan I; Fujimoto J; Alam SM; Sato E; Sakaguchi H; Tamaya T
Oncol Rep; 2007 Feb; 17(2):345-50. PubMed ID: 17203172
[TBL] [Abstract][Full Text] [Related]
23. The expression ratios of estrogen receptor α (ERα) to estrogen receptor β1 (ERβ1) and ERα to ERβ2 identify poor clinical outcome in endometrioid endometrial cancer.
Zannoni GF; Monterossi G; De Stefano I; Gargini A; Salerno MG; Farulla I; Travaglia D; Vellone VG; Scambia G; Gallo D
Hum Pathol; 2013 Jun; 44(6):1047-54. PubMed ID: 23266443
[TBL] [Abstract][Full Text] [Related]
24. [Expression and amplification of steroid receptor coactivator-3 gene in colorectal carcinoma and its clinicopathological significance].
Zeng SD; Xie D; Lin F; Wang CX; Tao Y; Zhang M
Zhonghua Wei Chang Wai Ke Za Zhi; 2005 Jan; 8(1):67-70. PubMed ID: 16149006
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of ephrinB2 and EphB4 in tumor advancement of uterine endometrial cancers.
Alam SM; Fujimoto J; Jahan I; Sato E; Tamaya T
Ann Oncol; 2007 Mar; 18(3):485-90. PubMed ID: 17108150
[TBL] [Abstract][Full Text] [Related]
26. Role of the steroid receptor coactivator SRC-3 in cell growth.
Zhou G; Hashimoto Y; Kwak I; Tsai SY; Tsai MJ
Mol Cell Biol; 2003 Nov; 23(21):7742-55. PubMed ID: 14560019
[TBL] [Abstract][Full Text] [Related]
27. Amplified in breast cancer 1 in human epidermal growth factor receptor - positive tumors of tamoxifen-treated breast cancer patients.
Kirkegaard T; McGlynn LM; Campbell FM; Müller S; Tovey SM; Dunne B; Nielsen KV; Cooke TG; Bartlett JM
Clin Cancer Res; 2007 Mar; 13(5):1405-11. PubMed ID: 17332282
[TBL] [Abstract][Full Text] [Related]
28. Polymorphic CAG/CAA repeat length in the AIB1/SRC-3 gene and prostate cancer risk: a population-based case-control study.
Hsing AW; Chokkalingam AP; Gao YT; Wu G; Wang X; Deng J; Cheng J; Sesterhenn IA; Mostofi FK; Chiang T; Chen YL; Stanczyk FZ; Chang C
Cancer Epidemiol Biomarkers Prev; 2002 Apr; 11(4):337-41. PubMed ID: 11927493
[TBL] [Abstract][Full Text] [Related]
29. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma.
Cirisano FD; Robboy SJ; Dodge RK; Bentley RC; Krigman HR; Synan IS; Soper JT; Clarke-Pearson DL
Gynecol Oncol; 2000 Apr; 77(1):55-65. PubMed ID: 10739691
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma.
Fukuda K; Mori M; Uchiyama M; Iwai K; Iwasaka T; Sugimori H
Gynecol Oncol; 1998 Jun; 69(3):220-5. PubMed ID: 9648591
[TBL] [Abstract][Full Text] [Related]
31. Differential methylation hybridization array of endometrial cancers reveals two novel cancer-specific methylation markers.
Zighelboim I; Goodfellow PJ; Schmidt AP; Walls KC; Mallon MA; Mutch DG; Yan PS; Huang TH; Powell MA
Clin Cancer Res; 2007 May; 13(10):2882-9. PubMed ID: 17504987
[TBL] [Abstract][Full Text] [Related]
32. Fatty acid synthase is a potential therapeutic target in estrogen receptor-/progesterone receptor-positive endometrioid endometrial cancer.
Rahman MT; Nakayama K; Ishikawa M; Rahman M; Katagiri H; Katagiri A; Ishibashi T; Iida K; Miyazaki K
Oncology; 2013; 84(3):166-73. PubMed ID: 23306391
[TBL] [Abstract][Full Text] [Related]
33. Tumor budding and E-Cadherin expression in endometrial carcinoma: are they prognostic factors in endometrial cancer?
Koyuncuoglu M; Okyay E; Saatli B; Olgan S; Akin M; Saygili U
Gynecol Oncol; 2012 Apr; 125(1):208-13. PubMed ID: 22198340
[TBL] [Abstract][Full Text] [Related]
34. E6AP mediates regulated proteasomal degradation of the nuclear receptor coactivator amplified in breast cancer 1 in immortalized cells.
Mani A; Oh AS; Bowden ET; Lahusen T; Lorick KL; Weissman AM; Schlegel R; Wellstein A; Riegel AT
Cancer Res; 2006 Sep; 66(17):8680-6. PubMed ID: 16951183
[TBL] [Abstract][Full Text] [Related]
35. The steroid receptor coactivator-3 is a tumor promoter in a mouse model of thyroid cancer.
Ying H; Willingham MC; Cheng SY
Oncogene; 2008 Jan; 27(6):823-30. PubMed ID: 17653082
[TBL] [Abstract][Full Text] [Related]
36. [Clinical implications of positive peritoneal cytology in endometrial cancer].
Ren YL; Wang HY; Shan BE; Ping B; Shi DR
Zhonghua Fu Chan Ke Za Zhi; 2011 Aug; 46(8):595-9. PubMed ID: 22169518
[TBL] [Abstract][Full Text] [Related]
37. Androgen and estrogen receptors and co-regulators levels in endometria from patients with polycystic ovarian syndrome with and without endometrial hyperplasia.
Villavicencio A; Bacallao K; Avellaira C; Gabler F; Fuentes A; Vega M
Gynecol Oncol; 2006 Oct; 103(1):307-14. PubMed ID: 16677694
[TBL] [Abstract][Full Text] [Related]
38. Cyclin E Expression Correlates with Cancer-specific Survival in Endometrial Endometrioid Adenocarcinoma.
Santala S; Talvensaari-Mattila A; Soini Y; Santala M
Anticancer Res; 2015 Jun; 35(6):3393-7. PubMed ID: 26026100
[TBL] [Abstract][Full Text] [Related]
39. Tissue and serum biomarkers as prognostic variables in endometrioid-type endometrial cancer.
Gadducci A; Cosio S; Genazzani AR
Crit Rev Oncol Hematol; 2011 Nov; 80(2):181-92. PubMed ID: 21134766
[TBL] [Abstract][Full Text] [Related]
40. [Prognostic factors in diagnosed endometrial cancers determining the type of radical surgery].
Ivanov S; Tomov S
Akush Ginekol (Sofiia); 2009; 48(3):14-9. PubMed ID: 20198758
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
